• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

CeQur wins FDA nod for mealtime insulin delivery device

July 1, 2024 By Sean Whooley

CeQur Simplicity
The CeQur Simplicity wearable insulin delivery device. [Image courtesy of CeQur]
CeQur announced recently that the FDA granted 510(k) clearance for its Simplicity system for an extended wear duration.

Clearance extends the wear time for the wearable mealtime insulin delivery patch from three to four days. It marks a significant advancement for what the company says is the longest wearable insulin delivery patch, which provides diabetes discretion, additional convenience and injection-free dosing.

Each patch now replaces up to 12 mealtime injections, equaling more than 1,000 fewer injections annually, according to a news release.

Simplicity, a wearable, disposable bolus insulin delivery system, was developed as, essentially, a wearable insulin pen. CeQur began a pilot commercial launch for the FDA-cleared and CE-marked device in early 2021. In April 2021, the company raised $115 million to support that launch and scale up manufacturing.

President and CEO Bradley Paddock spoke to Drug Delivery Business News in 2022 about the benefits of Simplicity.

CeQur said it has a fully automated manufacturing line to support 100,000 patients. It also increased the size of its sales force to ensure wider availability for Simplicity.

“We are excited to share that there are now ~5000 people with diabetes using CeQur Simplicity for their mealtime insulin delivery,” said Paddock. “With the 4-day clearance, we hope to make it even easier for people with diabetes to take their mealtime insulin.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: cequr, FDA

IN CASE YOU MISSED IT

  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS